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Introduction
Adult patients receiving anti-TNFa treatment are at
increased risk for developing tuberculosis (TB). Few
data have been published in the pediatric population.
Objectives
We describe the occurrence of latent tuberculosis infec-
tion (LTI) and TB in children and adolescents treated
with anti-TNFa agents.
Methods
Cohort observational study including pediatric patients
receiving anti-TNFa agents in a tertiary-care pediatric
hospital. LTI is ruled out by the implementation of anti-
TNFa drugs by tuberculin skin test (TST) and, from
March 2012, QuantiFERON Gold-In Tube® test (QTF).
Along treatment, patients are evaluated periodically for
TB using history and physical examination, but TST/
QTF are not systematically repeated.
Results
The final cohort consisted of 261 anti-TNFa treatments
in 221 patients (56.1% female), of whom 51.7%/31.
%/17.2% treated with etanercept/adalimumab/infliximab,
respectively, for a variety of rheumatic diseases (75.6%),
inflammatory bowel disease (20.8%) and inflammatory
eye diseases (3.6%). The mean(SD) age at diagnosis of
the primary condition was 7.2(4.6) years and the dura-
tion of the disease before implementing the anti-TNFa
agent was 3.0(3.3) years. The total follow-up time under
anti-TNFa treatment was 614 patients-year; mean(SD)
time per patient: 2.8(2.2) years.
LTI was diagnosed in 3 adolescent girls (prevalence
rate: 1.4%; 95%CI: 0-2.9) affected with juvenile idiopathic
arthritis, who received isoniazid chemoprophylaxis and
were later treated with anti-TNFa, without incidences.
QTF tested positive in all three patients, while TST was
positive in only one of them. No incident cases of TB
were observed.
Conclusion
In our study, the prevalence of LTI (1.4%) was similar to
that reported in population screening studies in Spain
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